Guardant Health, Inc.
GH
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $21.9B
$161.29
▼ -1.09%
P/E
-46.21
Mkt Cap
$21.9B
52-Wk Range
$53.40–$176.58
52-Week Range
$53.40 - $176.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 150.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Market-leading liquid biopsy platform with extensive clinical validation and real-world evidence
- Proprietary clinical-genomic dataset of advanced cancer patients enabling superior analytics and insights
- Integrated ecosystem connecting diagnostics, data, software, and clinical trial matching
- Strong relationships with oncologists, biopharmaceutical companies, and healthcare systems
- Regulatory approvals including FDA breakthrough designations and companion diagnostic certifications
- Continuous innovation pipeline with early detection and treatment selection applications
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Moderate growth ahead
Expansion of liquid biopsy adoption in early-stage cancer detection and treatment monitoring
Value
Trading at 0.0x Life Sciences Tools peers — a discount despite the growth profile.
Momentum
Hot
+28.4% over 3m
Quality
Excellent
High-growth business (43% revenue growth, 65% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying GH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 30, 2026
Reported EPS of -$0.90 vs -$0.76 consensus (-18.1% surprise). Revenue of $335.0M vs $314.2M expected (+6.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-18.1%
Revenue trend · last 8Q
—
+30%
+21%
+31%
+39%
+39%
+48%
+44%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$191.5M
$201.8M
$203.5M
$232.1M
$265.2M
$281.3M
$301.7M
$335.0M
Margins · last 8Q
Gross
65.4%
Operating
-38.5%
Profit
-35.9%
Wall Street consensus
13 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$160.00
▼ -0.8% vs $161.29
Latest: TD Cowen · Aug 25, 2026
1 analyst covering
vs Industry
How GH stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related